Schizophrenic symptoms improve with apomorphine

Carol A. Tamminga, Martin H. Schaffer, Robert C. Smith, John M. Davis

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.

Original languageEnglish (US)
Pages (from-to)567-568
Number of pages2
JournalScience
Volume200
Issue number4341
StatePublished - 1978

Fingerprint

Apomorphine
Placebos
Presynaptic Receptors
Dopamine Agonists
Dopamine Receptors
Synaptic Transmission
Dopamine

ASJC Scopus subject areas

  • General

Cite this

Tamminga, C. A., Schaffer, M. H., Smith, R. C., & Davis, J. M. (1978). Schizophrenic symptoms improve with apomorphine. Science, 200(4341), 567-568.

Schizophrenic symptoms improve with apomorphine. / Tamminga, Carol A.; Schaffer, Martin H.; Smith, Robert C.; Davis, John M.

In: Science, Vol. 200, No. 4341, 1978, p. 567-568.

Research output: Contribution to journalArticle

Tamminga, CA, Schaffer, MH, Smith, RC & Davis, JM 1978, 'Schizophrenic symptoms improve with apomorphine', Science, vol. 200, no. 4341, pp. 567-568.
Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science. 1978;200(4341):567-568.
Tamminga, Carol A. ; Schaffer, Martin H. ; Smith, Robert C. ; Davis, John M. / Schizophrenic symptoms improve with apomorphine. In: Science. 1978 ; Vol. 200, No. 4341. pp. 567-568.
@article{81327ecedf3f482b8ee63e0635f524f2,
title = "Schizophrenic symptoms improve with apomorphine",
abstract = "Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.",
author = "Tamminga, {Carol A.} and Schaffer, {Martin H.} and Smith, {Robert C.} and Davis, {John M.}",
year = "1978",
language = "English (US)",
volume = "200",
pages = "567--568",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4341",

}

TY - JOUR

T1 - Schizophrenic symptoms improve with apomorphine

AU - Tamminga, Carol A.

AU - Schaffer, Martin H.

AU - Smith, Robert C.

AU - Davis, John M.

PY - 1978

Y1 - 1978

N2 - Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.

AB - Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.

UR - http://www.scopus.com/inward/record.url?scp=0018099454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018099454&partnerID=8YFLogxK

M3 - Article

C2 - 347574

AN - SCOPUS:0018099454

VL - 200

SP - 567

EP - 568

JO - Science

JF - Science

SN - 0036-8075

IS - 4341

ER -